Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.

Archive ouverte

Petit, Jean-Michel | Cercueil, Jean-Pierre | Loffroy, Romaric | Denimal, Damien | Bouillet, Benjamin | Fourmont, Coralie | Chevallier, Olivier | Duvillard, Laurence | Verges, Bruno

Edité par CCSD ; Endocrine Society -

IF 5.455. International audience. Background:Nonalcoholic fatty liver disease is very frequent in type 2 diabetes, with increased risk of further development of liver fibrosis. Animal studies have shown that GLP-1 receptor agonists may reduce liver lipogenesis. However, data in humans are scarce.Objective:To study the effect of liraglutide 1.2 mg/d on liver fat content (LFC) in patients with uncontrolled type 2 diabetes and to evaluate the factors potentially associated with liraglutide-induced modification of LFC.Design, Setting, Participants:LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.Intervention:Liraglutide 1.2 mg/d.Outcome measure:Change in LFC.Results:Treatment with liraglutide was associated with a significant decrease in body weight, HbA1C, and a marked relative reduction in LFC of 31% (P < 0.0001). No significant modification of LFC was observed in a parallel group of patients 6 months after intensification of the antidiabetic treatment with insulin. The reduction in LFC and body weight were highly correlated (r = 0.490; P < 0.0001). In multivariate analysis, the reduction in LFC was independently associated with baseline LFC (P < 0.0001), age (P = 0.010), and reduction in body weight (P < 0.0001), triglycerides (P = 0.019), and HbA1c (P = 0.034). In the patients who had no significant decrease in body weight, no significant reduction in LFC was observed.Conclusions:Six months of treatment with liraglutide 1.2 mg/d significantly reduced LFC in patients with inadequately controlled type 2 diabetes and this effect was mainly driven by body weight reduction. Further studies are needed to confirm that this reduction in LFC may significantly reduce fibrosis progression.

Consulter en ligne

Suggestions

Du même auteur

Les guidelines des sociétés européennes de diabétologie et d’hépatologie concernant l’exploration et la prise en charge de la stéatose hépatique non-alcoolique ne sont pas adaptées aux patients diabétiques de type 2

Archive ouverte | Petit, Jean-Michel | CCSD

International audience

Effet d’un traitement par liraglutide sur la ferritinémie et le contenu hépatique en fer chez des patients diabétiques de type 2

Archive ouverte | Petit, Jean-Michel | CCSD

International audience

Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes

Archive ouverte | Petit, Jean-Michel | CCSD

IF 12.486. Lettre à l'éditeur ("Journal of Hepatology", vol. 68, n°3, pp. 603-604, available online 4 October 2017)https://www.sciencedirect.com/science/article/pii/S0168827817323292?via%3Dihub

Chargement des enrichissements...